Connect your AI

Pfizer PFE Debt Securities Maturities, After Year Five, Fair Value

Other financials

Income statement

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+5.0%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

Market cap$143.68B+11.1%

Enterprise value$206.35B+9.2%

P/E11.9×—

P/S2.3×+0.2×

Profitability

Gross margin73.5%+1.2pp

Net margin15.7%—

Returns & leverage

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's debt securities maturities, after year five, fair value.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pfizer's debt securities maturities, after year five, fair value?: Pfizer (PFE) reported debt securities maturities, after year five, fair value of $38M in Q1 2026.
How has Pfizer's debt securities maturities, after year five, fair value changed year-over-year?: Pfizer's debt securities maturities, after year five, fair value increased by 81.0% year-over-year, from $21M to $38M.